Dyne Therapeutics’ (DYN) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report report published on Tuesday morning,Benzinga reports. Chardan Capital currently has a $38.00 price objective on the stock.

A number of other brokerages have also recently weighed in on DYN. Sanford C. Bernstein set a $23.00 price target on shares of Dyne Therapeutics in a research report on Tuesday. Lifesci Capital raised shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Oppenheimer reduced their target price on shares of Dyne Therapeutics from $13.00 to $11.00 and set a “market perform” rating on the stock in a report on Wednesday, November 12th. Raymond James Financial reiterated a “strong-buy” rating and issued a $40.00 price target on shares of Dyne Therapeutics in a report on Monday. Finally, HC Wainwright boosted their price objective on Dyne Therapeutics from $46.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $36.71.

Dyne Therapeutics Price Performance

DYN stock opened at $18.44 on Tuesday. The company has a market cap of $2.63 billion, a PE ratio of -5.04 and a beta of 1.30. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The stock has a 50-day moving average price of $18.77 and a two-hundred day moving average price of $14.14. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $28.96.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.05. As a group, research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DYN. Darwin Wealth Management LLC lifted its holdings in Dyne Therapeutics by 0.5% in the third quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock worth $2,195,000 after acquiring an additional 861 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after purchasing an additional 955 shares during the period. Creative Planning boosted its stake in Dyne Therapeutics by 6.8% during the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after buying an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after purchasing an additional 1,109 shares during the period. Finally, Caxton Associates LLP lifted its holdings in shares of Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after purchasing an additional 1,627 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.